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GUEST EDITORIAL
Chronic kidney disease
In the USA, the proportion of the population with chronic kidney 
disease (CKD) reached 15% by 2017.[1] In South Africa (SA), this 
figure may well be higher. CKD management in the developed world 
aims at the apex of the triangle, e.g. improvements in dialysis and 
transplantation, as well as the mid-triangle area, i.e. strategies in 
slowing the progression to end-stage renal disease. In SA, however, 
the huge costs of dialysis and transplantation dictate that our CKD 
management should first and foremost be aimed at prevention and, 
secondly, at renoprotection. The review presented in the CME sec-
tion of SAMJ[2] highlights recent information relating to the use of 
metformin in the management of diabetes in patients with CKD, the 
essential and early treatment of CKD acidosis (i.e. estimated glome-
rular filtration rate (eGFR) ≤59 mL/min), early dietary therapy, 
early lowering of serum uric acid and the introduction of adequate 
and ongoing exercise – all aimed at slowing the progression of CKD. 
Furthermore, the use of high-dose statins in preventing cyst growth 
and eventual renal failure in patients with autosomal-dominant poly-
cystic disease is explained.
One development not mentioned in the review, is the pivotal 
importance of vitamin D metabolism and secondary hyperpara-
thyroidism (sHPT) in renoprotection. Effective treatment of sHPT 
significantly reduces the risk of myocardial infarction, stroke and 
heart failure; therefore, correct management is essential. This is 
discussed in an article by Friedl and Zitt[3] on vitamin D pro-
hormone in the treatment of sHPT in patients with CKD. Early in 
CKD (stage 2), the osteocyte begins to produce increased levels of 
fibroblast growth factor 23 (FGF23), and by CKD stages 3a and 3b 
the levels are >1 000 times increased. With every decrement of the 
GFR, phosphate retention would tend to occur, but is offset by an 
even higher secretion of FGF23. Given the inexorable fall in GFR, 
sooner or later the serum phosphate will be permanently increased. A 
reduction in dietary phosphate ingestion is mandatory for all patients 
with CKD stage 3 and onwards.
Sunlight converts epidermal vitamin D2 into inactive vitamin D3 
(calciferol), which is stored in the liver. However, large quantities are 
also stored in adipose tissue of obese persons. Low levels of circulating 
vitamin D3 are commonly found in CKD stage 3a onwards,  especially 
in overweight patients. FGF23 inhibition of the reabsorption of tubular 
phosphate results in intermittent hypophosphataemia, which occurs 
early on in CKD. Moreover, the increased FGF23 markedly inhibits 
the action of the proximal tubular 1α-hydroxylase enzyme responsible 
for the conversion of calciferol to calcitriol (1,25(OH)2D3). Low levels 
of active vitamin D3 result in a marked decrease in the absorption of 
dietary calcium, resulting in intermittent hypocalcaemia and sHPT. 
Prevention of sHPT should start early, when the eGFR is ≤60 mL/min. 
Early administration of calcitriol has resulted in accelerated coronary 
and carotid artery calcification. However, the administration of rela-
tively large doses of calciferol (20 000 - 30 000 IU weekly) on a permanent 
basis is safe, and will not lead to hypercalcaemia or metastatic vascular 
calcification. The extent to which this strategy is effective in preventing 
sHPT is still a matter of debate, but does form part of the most recent 
recommendations.[4] Calcitriol in a dose of 0.25 µg/day should be intro-
duced only when the eGFR has decreased to <20 mL/min.
Finally, it is in the hands of our general practitioners and primary 
healthcare workers to diagnose CKD early and to either introduce 
adequate therapy or to refer early. Future government support for a 
prevention programme is also absolutely essential, but is currently 
not provided for. 
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